

# medicina intensiva

medicina Internsiva

Internsiv

http://www.medintensiva.org/en/

# ORIGINAL ARTICLE

# Early mobilisation in patients with shock and receiving vasoactive drugs in the intensive care unit: A systematic review and meta-analysis of observational studies



Henry Mauricio Parada-Gereda<sup>a,\*</sup>, Luis F. Pardo-Cocuy<sup>b</sup>, Janneth Milena Avendaño<sup>c</sup>, Daniel Molano-Franco<sup>d</sup>, Joan Ramón Masclans<sup>e</sup>

- <sup>a</sup> Unidad de Cuidado Intensivo Clínica Reina Sofia, Clínica Colsanitas, Grupo de Investigación en Nutrición Clínica y Rehabilitación, Grupo Keralty, Fundacion Universitaria Sanitas, Bogotá, Colombia
- <sup>b</sup> Unidad de Cuidado Intensivo Hospital Universitario Mederi Mayor, Universidad del Rosario, Bogotá, Colombia
- <sup>c</sup> Unidad de Cuidado Intensivo Clínica Reina Sofia Pediátrica y Mujer, Clínica Colsanitas, Grupo de Investigación en Nutrición Clínica y Rehabilitación, Fundacion Universitaria Sanitas, Grupo Keralty, Bogotá, Colombia
- <sup>d</sup> Intensive Care Unit Los Cobos Medical Center- Hospital San José, Research Group Gribos, Bogotá, Colombia
- <sup>e</sup> Critical Care Department, Hospital Del Mar Barcelona, Spain, Critical Care Illness Research Group (GREPAC), IMIM, Department of Medicine and Life Sciences (MELIS), Universitat Pompeu Fabra (UPF), Barcelona, Spain

Received 26 July 2024; accepted 16 September 2024 Available online 17 November 2024

### **KEYWORDS**

Early mobilization; Intensive care unit; Muscle weakness; Shock; Vasoconstrictor drugs

### Abstract

*Objective*: The aim of the study was to assess the feasibility and safety of early mobilisation in patients with shock requiring vasoactive drugs in the intensive care unit (ICU).

Design: Systematic review and meta-analysis.

Setting: Intensive care unit (ICU).

Patients or participants: Adult patients requiring vasoactive drugs who received early mobilisation in the intensive care unit.

Interventions: A systematic search was conducted using the databases PubMed, Cochrane Library, Scopus, Medline Ovid, Science Direct, and CINAHL, including observational studies involving adult patients requiring vasoactive drugs who received early mobilisation. A meta-analysis was performed on the proportion of safety events and the proportion of early mobilisation in patients with high, moderate, and low doses of vasoactive drugs.

Main variables of interest: Feasibility, safety events, and the maximum level of activity achieved during early mobilisation.

E-mail address: maoparada1606@gmail.com (H.M. Parada-Gereda).

<sup>\*</sup> Corresponding author.

Results: The search yielded 1875 studies, of which 8 were included in the systematic review and 5 in the meta-analysis. The results showed that 64% (95% CI: 34%–95%, p < 0.05) of patients were mobilised with low doses of vasoactive drugs, 30% (95% CI: 7%–53%, p < 0.05) with moderate doses, and 7% (95% CI: 3%–16%, p 0.17) with high doses. The proportion of adverse events was low, at 2% (95% CI: 1%–4%, p < 0.05).

Conclusions: Early mobilisation in patients with shock and the need for vasoactive drugs is feasible and generally safe. However, there is an emphasis on the need for further high-quality research to confirm these findings.

© 2024 Elsevier España, S.L.U. and SEMICYUC. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

### PALABRAS CLAVE

Movilización temprana; Unidad de cuidados intensivos; Debilidad muscular; Shock; Fármacos vasoconstrictores Movilización temprana en pacientes con shock y que reciben fármacos vasoactivos en la unidad de cuidados intensivos: una revisión sistemática y metaanálisis de estudios observacionales

#### Resumen

Objetivo: El objetivo del estudio fue evaluar la viabilidad y seguridad de la movilización temprana en pacientes con shock que requieren drogas vasoactivas en la unidad de cuidados intensivos (UCI).

Diseño: Revisión sistemática y metaanálisis. Ámbito: Unidad de cuidados intensivos (UCI).

Pacientes y participantes: Pacientes adultos que requieren drogas vasoactivas y que recibieron movilización temprana en la unidad de cuidados intensivos.

Intervenciones: Se realizó una búsqueda sistemática utilizando las bases de datos PubMed, Cochrane Library, Scopus, Medline Ovid, Science Direct y CINAHL, se incluyeron estudios observacionales que involucraban a pacientes adultos que requerían drogas vasoactivas y recibieron movilización temprana. Se realizó un metaanálisis sobre la proporción de eventos de seguridad y la proporción de movilización temprana en pacientes con dosis altas, moderadas y bajas de drogas vasoactivas.

Variables de interés principales: Viabilidad, eventos de seguridad y el nivel máximo de actividad alcanzado durante la movilización temprana.

Resultados: La búsqueda arrojó 1875 estudios, de los cuales 8 fueron incluidos en la revisión sistemática y 5 en el metaanálisis. Los resultados mostraron que el 64% (IC 95%: 34%-95%, p < 0.05) de los pacientes fueron movilizados con dosis bajas de drogas vasoactivas, el 30% (IC 95%: 7%-53%, p < 0.05) con dosis moderadas y el 7% (IC 95%: 3%-16%, p = 0.17) con dosis altas. La proporción de eventos adversos fue baja, del 2% (IC 95%: 1%-4%, p < 0.05).

Conclusiones: La movilización temprana en pacientes con shock y necesidad de drogas vasoactivas es viable y generalmente segura. Sin embargo, se enfatiza la necesidad de realizar más investigaciones de alta calidad para confirmar estos hallazgos.

 $\odot$  2024 Elsevier España, S.L.U. y SEMICYUC. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares.

### Introduction

Adult patients admitted to intensive care units (ICU) requiring during long periods invasive ventilatory support, sedation, and neuromuscular blockade will develop neuromuscular, cognitive, and respiratory complications. ICU-acquired muscle weakness (ICUAW) is a frequent complication of critical illness, occurring in approximately 50% of ICU patients associated to sedation and prolonged bed rest and is strongly associated with increased morbidity, physical impairment, and short- and long-term mortality. 2,3 The consequences of critical illness and therapies administered

in the ICU persist beyond hospital discharge and may contribute to poor post-ICU recovery.  $^{4-6}$ 

Early mobilisation in the ICU appears to be feasible and safe.<sup>7-9</sup> The beneficial effects of different early mobilisation strategies are associated with prevention of ICUAW, maintenance of peripheral and respiratory muscle strength, reduction of time on mechanical ventilation and weaning, reduction of ICU and hospital stay, and improvement of patients' quality of life<sup>10-13</sup>; However, it is important to emphasise that there is significant heterogeneity in the definition of ''early mobilization'' in different studies.<sup>14,15</sup> There is consensus that early mobilisation refers

to any form of physical activity within 72 hours of ICU admission.  $^{14,16,17}$ 

Several authors have shown that haemodynamic instability and the use of vasoactive drugs are barriers to the active mobilisation of ICU patients, which can delay the initiation of early mobilization. <sup>18–20</sup> Wolfe et al. showed that the use of vasoactive drugs was independently associated with the development of ICU-acquired weakness. <sup>21</sup> The aim of this systematic review is to compile the best evidence for the feasibility and safety outcome of early mobilisation in patients with shock and need for vasoactive drugs in the ICU.

# **Methods**

A systematic review was conducted that included prospective and retrospective cohort studies of patient's ≥18 years with vasoactive drug requirements undergoing early mobilisation in the intensive care unit. The protocol of the systematic review was registered in the CRD42024561501 database of the Prospective International Registry of Systematic Reviews (PROSPERO), and the systematic review was performed according to the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).<sup>22</sup>

The evaluation of methodological quality was performed independently by two investigators; the Newcastle-Ottawa quality assessment scale was used, 23 on this scale, scores of seven stars indicate high quality, scores between four and six stars moderate quality, and fewer than four stars poor quality, followed by the kappa coefficient to assess inter-investigator agreement. The certainty of the evidence was evaluated using the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) methodology.<sup>24</sup>

This systematic review was conducted in accordance with international ethical principles and systematic review guidelines. As it is based on the collection and analysis of data from previously published studies, informed consent from participants was not required. The review was carried out in compliance with research ethics regulations and standards for scientific evidence synthesis.

# Eligibility criteria

This systematic review and meta-analysis included prospective and retrospective cohort studies of ICU patients that analysed early mobilisation and the safety of patients aged ≥18 years receiving any vasoactive drug at any dose in the intensive care unit. The studies had to report the number of sessions conducted with vasoactive drugs, the maximum level of activity achieved, and the safety events associated with early mobilisation (or any of these variables). It was required that the studies be in full text to access the results completely. Studies that included paediatric patients and those that did not include any of the described variables were excluded. There were no restrictions on date or language.

Early mobilisation was defined as any form of physical activity within the first 72 hours of ICU admission, including

passive mobilisations and the use of assistive technologies such as neuromuscular electrical stimulation.

### Search strategy

Two investigators conducted independent systematic literature searches of PubMed, Cochrane Library, Scopus, Medline Ovid, Science Direct and CINAHL databases published from inception to October 30 2023; discrepancies between the two investigators were resolved with the intervention of a third investigator. The terms "early mobilisation", "intensive care unit", "critical illness" "vasoconstrictor agents", "muscle weakness" "exercise" "physical therapy modalities" and articles in all languages were included, the complete search strategy is described in Supplementary file 1.

### Inclusion criteria

Prospective or retrospective observational cohort studies analysing early mobilisation or physical rehabilitation and the safety of patients aged  $\geq 18$  years receiving any vasoactive drug at any dose in the intensive care unit will be included.

### **Exclusion criteria**

Non-primary studies, those whose unit of analysis was not the patient, case reports, editorials, correspondence and studies that did not report the number of patients who received vasoactive drugs.

### Statistical analysis

Stata 18 software was utilised to conduct a meta-analysis on the proportion of patients undergoing early mobilisation with low, moderate, and high doses of vasoactive drugs, as well as the proportion of reported safety events associated with mobilisation. Confidence intervals of 95% were computed for these proportions. Heterogeneity was assessed using the  $I^2$  statistic, considered present if  $I^2 > 50\%$ . Random-effects models were employed in cases of heterogeneity; otherwise, a fixed-effects model was applied. Publication bias was evaluated using funnel plots and Begg's and Egger's tests.

# Data synthesis and extraction

A predetermined form was used to extract the following information from the included articles: first author and year of publication, country of the first author, study design, sample size, age, characteristics of included patients, number of patients receiving vasoactive drugs, type and dose of vasoactive drugs, number of mobilisation sessions, maximum level of activity achieved, and safety events.

### Identification of studies via databases and registers




Figure 1 Study selection flowchart.

# Results

The initial search retrieved 1875 articles from seven databases, 1002 duplicates were removed, and 827 articles were excluded based on titles and abstracts, leaving 46 articles; full texts were then reviewed, 30 articles were excluded, and an additional 8 articles were excluded for not reporting the number of patients requiring vasoactive drugs. The systematic review included eight articles, of which five were included in the meta-analysis, totaling 13,143 patients (the detailed PRISMA flow diagram is shown in Fig. 1).

### Characteristics of the included studies

The different characteristics of the studies are listed in Table 1. Four prospective cohort studies, <sup>19,25-27</sup> and four retrospective cohort studies<sup>21,28-30</sup> were included. The

included studies were published between 2016 and 2022 and were conducted in different countries such as Belgium<sup>31</sup>; USA<sup>21,28</sup>; Australia<sup>19,25,29</sup>; Germany<sup>30</sup>; and Brazil.<sup>26</sup> Two studies were performed in postoperative cardiovascular surgery patients<sup>25,28</sup>; two studies were performed in patients with mechanical ventilation (MV) greater than 24 hours<sup>19,21</sup>; and four studies were performed in mixed ICUs.<sup>26,27,29,30</sup> The mean age of study participants was approximately 60+/-3.8 years.

# Type of vasoactive drugs used and number of sessions/patients

In the included studies, a total of 4604 patients received various vasoactive drugs at different doses, and 4292 sessions of early mobilisation with vasoactive drug infusion were performed. The most commonly used vasoactive drug

Authors	Design	n	Age	Patient characteris- tics	Number of patients who received vasoactive drugs	Vasoactive Drug/dose	Feasibility # mobilisation sessions	Maximum level of activity achieved	Security events
dickmann et al. 2016 Belgium	Prospective observa- tional study	171	59±17	Patients in mixed ICU	58 patients.	Mean dose of 0.10 μg/kg/min.	361 activities with nora- drenaline	Patients requiring noradrenaline >0.2 µg/kg/min (mean dose: 0.34) underwent bed-to-chair transfer for 11 sessions.	10 safety events 0.8% of the total number of interventions. Hypotension occurred in 2 patients receiving low-dose vasoactives, hypertension in 2 and tachycardia in three patients.
lievera et al. 2017 USA	Retrospective cohort study		64.3 ± 13.6	Cardiothorac surgery postopera- tive patients	ic47 patients	The norepinephrine dose ranged from 0.01 to 0.28 µg/kg/min with a mean of 0.056 µg/kg per minute.	Not reported	Ambulation more than 150 feet (45 m) at a dose of 0.1 mcg/kg/min	None
Wolfe et al. 2018 USA	Secondary analysis of RCT retro- spective study.	172	Group ICU- AW 61 (49-72) without ICU AW- 50 (31-64)	Patients on mechanical ventilation >24 hours and < 72 hours	90 patients	ICU-AW norepinephrine 60%. Without ICU-AW norepinephrine 24% ICU-AW vasopressin 48% Without ICU-AW vasopressin 22% ICU-AW phenylephrine 31% Without ICU-AW Phenylephrine 5%	Not reported	Limb muscle strength training	No reported
Capell et al. 2019 Australia	Prospective observa- tional study	100	55.5	MV >24 hours	54 sessions	>10 mcg/min in bed, 1 patient out of bed with a dose of 4 mcg/min	280	March in place (IMS 6)	None

respiratory,5

minor events,<sup>8</sup>
1 serious event

successful CBR.

agitation,3

				vasoactive drugs				
Rebel et al. 2019 Australia	Retrospective 119 cohort study	68±11	Medical, surgical and trauma ICUs	119 patients,	Vasoactive drug doses were low in 77%, medium in 14% and high in 9% of vasoactive days. Norepinephrine was administered on 74.4% of vasoactive days with a mean dose of 6.7 µg/min.	195 sessions of mobilisation with vasoactive agent	Walk outside the bed/chair for at least 5 metres.	O serious events, 14 episodes of hypotension requiring increased vasoactive medication, 1 new onset of arrhythmia without subsequent medical intervention.
Boyd et al. 2020 Australia	Single- 20 center prospective observa- tional study	$65.9 \pm 10.6$	Postoperative cardiovascu- lar surgery patients	e 20 patients	Six participants were classified as receiving low dose, 13 as moderate dose and 1 as high dose vasoactive medication (noradrenaline-dopamine-adrenaline-vasopressin) all received dopamine mean dose 3.89 [1.12] mcg/kg/min.	Not reported	Standing	Low severity hypotension in 1 patient.
Borges et al. 2022 Brasil	Prospective 53 cohort study	70,3 ± 16,7	Patient in surgical and medical ICU	53 patients	70% of patients on low doses of vasoactive agents, 67% of patients on moderate doses and 65% of patients on high doses of vasoactive agents were mobilized.	with	Walk outside the bed/chair for at least 5 metres.	2 hypotension events with mean pressure <70 mmhg.
Lindholz et al. 2022 Germany	Retrospective 12462 cohort study	66.0 (54.0- 77.0)	Patients 16 ICUs of a	4217 patients,	The 95th percentile was 0.33 µg/kg/min for in-bed	3306 sessions	Walking with assistance of 2	Cardiovascular events, 30

Vasoactive Drug/dose

mobilization (IMS 0-1) and

out-of-bed mobilisation

 $0.20 \,\mu g/kg/min$  for

 $(IMS \ge 2)$ .

with

vasoactive.

or more

persons

Feasibility # Maximum level Security events

achieved

mobilisation of activity

sessions

MV: Mechanical ventilation; CBR: cardiopulmonary brain resuscitation; MCG/MIN: microgram/minute; µg/kg/min: microgram/kilogram/minute; NORA: noradrenaline; ICUAW: Intensive care unit acquired weakness; IMS: ICU mobility scale; ICU: Intensive Care Unit.

Table 1

**Authors** 

(Continued)

Design

of a single-

center

without

nora, 67.0

(56.0, 77.0)

with nora

university

hospital

n

Age

Patient

tics


characteris-


Number of


received

patients who

vasoactive drugs







**Figure 2** Proportion of patients who underwent early mobilisation with low, moderate, and high doses of vasoactive drugs.

(A) Proportion of patients who underwent early mobilisation with low doses. (B) Proportion of patients who underwent early mobilisation with moderate doses. (B) Proportion of patients who underwent early mobilisation with high doses.

in the studies was noradrenaline  $^{19,21,25-30}$ ; additionally, other authors reported the use of vasopressin  $^{21,25,26}$ ; adrenaline  $^{25}$ ; phenylephrine  $^{21,25}$ ; dopamine  $^{25}$ ; Dobutamine,  $^{26}$  Milrinone.  $^{26}$ 

### Type of vasoactive drugs and doses used

Three studies reported on early mobilisation performed with different doses of vasoactive drugs.  $^{28-30}$  The proportion of patients who underwent early mobilisation with low doses of vasoactive drugs was 64% (95% CI 34%–95%) p < 0.05 I<sup>2</sup> 99%; with moderate doses was 30% (95% CI 7%–53%) p < 0.05 I<sup>2</sup> 98%; and with high doses was 7% (95% CI 3%–16%) p 0.17 I<sup>2</sup> 98% can be seen in Fig. 2. The classification of the most commonly used doses of vasoactive drugs (including inotropics and vasopressors) can be seen in Table 2.

# Details of intervention and level of activity carried out

All studies included early mobilisation involving exercises assisted by patients. Four studies quantified the level of activity achieved with the ICU mobility scale (IMS). <sup>19,26,29,30</sup> In the following studies, the maximum level of activity achieved with vasoactive drug infusion is reported: in the study by Capell et al., <sup>19</sup> the maximum level of activity achieved was exercises out of bed; Nievera et al., <sup>28</sup> achieved active transfer to a chair or ambulation in the first 24 to 72 hours after surgery; Boyd et al., <sup>25</sup> performed positional changes and low-level exercises after cardiac surgery; Borges et al., <sup>26</sup> mobilised patients at low intensity (IMS 1 and 2); Wolfe et al., <sup>21</sup> conducted muscle strength training; Hickman et al., <sup>27</sup> reported standing and walking exercises; Rebel et al., <sup>29</sup> reported active mobilisation out of bed,

Drug Name	Low Dose, μg/kg/min	Moderate Dose, μg/kg/min	High Dose, μg/kg/min
Dopamine	<3	3-10	>10
Dobutamine	<3	3-10	>10
Epinephrine	<0.05	0.05-0.2	>0.2
Norepinephrine	<0.05	0.05-0.2	>0.2
Vasopressin	<0.01	0.02-0.03	0.04
Levosimendan	<0.05	0.1	0.2
Milrinone	0-0.15	0.15-0.5	0.5

ambulation, and marching in place; finally, Lindholz et al., <sup>30</sup> reported out-of-bed mobilisation as the maximum level of activity achieved.

### Security events

Five studies provided information on safety events in patients who underwent early mobilisation with vasoactive drug infusion  $^{19,26,27,29,30}$ ; The pooled proportion of adverse events from these studies was 2% (95% CI: 1%-4%) p < 0.05, I² 74.9% can be seen in Fig. 3. The most reported safety event was hypotension requiring increased vasoactive medications  $^{25-27,29,30}$ ; arterial hypertension and tachycardia was reported in two studies  $^{27,30}$ ; arrhythmia without subsequent medical intervention was reported in two studies  $^{29,30}$ ; In two studies, there were no safety events  $^{19,28}$ ; and finally, one study reported no safety events.  $^{21}$ 

### **Publication bias**

There was no significant publication bias in any of the outcomes. The results for publication bias were: proportion of early mobilisation performed in patients with low doses of vasoactive drugs, Egger's test (p = 0.79), Begg's test (p = 1.0); proportion of early mobilisation performed in patients with moderate doses of vasoactive drugs, Egger's test (p = 0.97), Begg's test (p = 1.0); proportion of early mobilisation performed in patients with high doses of vasoactive drugs, Egger's test (p = 0.37), Begg's test (p = 1.0); and proportion of safety events during early mobilisation in patients with vasoactive drug infusion, Egger's test (p = 0.59), Begg's test (p = 0.8). A funnel plot is presented in Additional file.

# Evaluation of methodological quality

The results of the quality assessment of the included studies are shown in Table 2. There was agreement among the authors Cohen's Kappa 0.87 (95% CI 0.74–0.89). There were six studies of moderate quality<sup>19,25–29</sup> and two of high quality.<sup>21,30</sup> Most studies did not describe the derivation of the unexposed cohort<sup>19,25,27–29</sup>; in four studies (in some due to their nature) there was no controlled analysis of confounders<sup>19,25–27</sup>; in two studies there was no clarity on outcome assessment.<sup>25,28</sup> Details are described in Table 3. The certainty of the evidence was moderate for the outcomes studied (see Supplementary file).


# Subgroup analysis

Subgroup analyses were conducted for the proportion of safety events and for the proportion of mobilisation in patients with low, moderate, and high-dose vasoactive drug infusion, excluding studies that could cause heterogeneity using the leave-one-out strategy. After excluding the study by Rebel et al.,  $^{29}$  a decrease in the proportion of safety events to 1% (95% CI 1%–2%) was observed p < 0.05, and a decrease in heterogeneity to  $1^2$  0%. The subgroup analysis for the proportion of mobilisation in patients with low, moderate, and high-dose vasoactive drug infusion did not show a reduction in heterogeneity (see Supplementary file).

### Discussion

This systematic review included 8 studies with a total of 13,143 patients, demonstrating that early mobilisation in most patients with shock requiring vasoactive drugs can be feasible and safe, with a low proportion of safety events, provided that a strict assessment of each patient and their haemodynamic status is carried out to individualise interventions. However, the dosing of vasoactive drugs and the maximum level of activity achieved in relation to dosing are unclear. It is relevant to note that 6 studies are of moderate methodological quality, and the measured outcomes show significant heterogeneity.

Shock is a pathological state that results when the circulation is unable to deliver sufficient oxygen and nutrients to the cells and tissues. The resulting hypoxia, tissue hypoperfusion and cellular dysfunction can lead to multi-organ failure; if this is not treated in a timely and appropriate manner, it can lead to death. 31,32 The first step in managing shock is the optimisation of the volume status, along with the restoration of mean arterial pressure (MAP) and organ perfusion.33 The use of catecholamines is considered the cornerstone of hemodynamic treatment of shock; this therapeutic class includes dopamine, epinephrine, noradrenaline and phenylephrine.<sup>34</sup> Norepinephrine is the first choice followed by vasopressin or epinephrine in critically ill patients.<sup>35</sup> In the included studies, noradrenaline was the most commonly used vasoactive agent in patients undergoing early mobilisation. The included studies do not clearly describe the type of shock presented in the patients; however, they highlight the initial hemodynamic assessment that allows early mobilisation to be initiated in patients receiving vasoactive drugs.



**Figure 3** Proportion of safety events in patients with vasoactive infusion.

Only one systematic review has been published in recent years,<sup>35</sup> which concluded that mobilisation of ICU patients receiving vasoactive drugs appears to be safe, and current studies do not indicate serious safety events associated with mobilisation. Our research included 3 new articles, allowing us to increase the number of patients studied to 13,143 and 4,294 mobilisation sessions with vasoactive drugs; additionally, it is the first study to conduct a meta-analysis of the proportion of safety events and the proportion of patients who underwent early mobilisation with low, moderate, and high doses of vasoactive drugs. Consistent with the previous study, we demonstrate that early mobilisation in patients with shock and vasoactive drugs can be feasible and safe, provided there is adequate assessment to individualise the intervention.

In contrast to our findings, some studies evidenced that hemodynamic instability and the use of vasoactive drugs were an important barrier to early mobilization. 18,36,37

The relationship between the dose of vasoactive drugs and the level of mobility achieved could not be precisely determined due to the heterogeneity of the doses reported in some studies and the lack of information in others. Lindholz et al.,30 concluded that doses of up to 0.20 mcg/kg/min for out-of-bed mobilisation (IMS > 2) and doses of up to 0.33 mcg/kg/min for in-bed mobilisation (IMS 0-1) appear to be safe; however, given the retrospective nature of the study these findings cannot be generalized; additionally, Rebel et al.<sup>29</sup> concluded that patients who received low levels of vasoactive drugs were more likely to mobilise; contrary to this, in another study the authors described that no significant relationship was found between the dose of norepinephrine and the level of activity achieved<sup>28</sup>; additionally Boyd et al., 25 was able to demonstrate that low level exercise in patients after cardiac surgery who received vasoactive drugs was well tolerated with a low incidence of adverse events and caused significant increases in mean arterial pressure (MAP) by improving cardiac output.

This study shows that the proportion of patients who underwent early mobilisation with the infusion of vasoactive drugs decreased as the dose of vasoactive drugs increased. The proportion decreased from 64% of patients mobilised with low doses to 30% with moderate doses, and to 7% with high doses. This demonstrates that the dosage of vasoactive drugs can be a barrier to mobilisation in the ICU.

The incidence of safety events in patients who underwent early mobilisation and received vasoactive drugs reported in the various included studies was low, and most were of low severity<sup>25–27,29,30</sup>; the proportion summarised in the meta-analysis was 2%, in agreement with a recent study that evidenced mobilisation in the ICU was associated with less than a 3% likelihood of an adverse event occurring.<sup>38</sup> Contrary to these findings, a recent study reported that 61.5% of patients in the early mobilisation group received vasoactive drugs and the incidence of safety events potentially due to mobilisation was 9.2%, concluding that the intervention was associated with safety events.<sup>39</sup> It is important to mention that we did not find unified definitions regarding the severity of safety events (serious and minor) in the studies included in this review.

A consensus of 23 experts on safety recommendations for active mobilisation in adults on mechanical ventilation described that it is relevant to perform a rigorous and individualized assessment of the patient's clinical conditions, the absolute dose of vasoactive drug and the dose change during mobilisation, concluding that the implementation of these recommendations has the potential to maximize early mobilisation and at the same time minimize the risk of adverse safety events; however, there was no consensus regarding the dose of vasoactive drugs (and the combination of these drugs) that would allow safe mobilisation in the ICU.<sup>40</sup> Additionally, several authors conclude that vasoactive infusions or mechanical ventilation are not barriers to initiating rehabilitation/mobilisation, provided that patients remain stable with the use of these therapies.<sup>41</sup>

The duration time of early mobilisation (daily and total) reported in the included studies was very heterogeneous, in agreement with other reviews where they report that such heterogeneity was mainly in the duration and frequency of individual interventions; additionally, the optimal dose for mobilisation remains uncertain. <sup>42</sup> This aspect is of great importance in patients receiving vasoactive drugs since the time of intervention could be a determinant of the patient's hemodynamic changes.

We can identify in the limitations of this study the potential biases that each of the studies included in this review may contain, as no randomised trials were included, the heterogeneity found in the meta-analysis results, the low number of studies, and the absence of a common reference value for the dose of vasoactive drugs for safe mobilisa-

Table 3 Results	Table 3         Results of the quality assessment of the included studies Newcastle-Ottawa Scale.	nent of the inclu	uded studies Ne	ewcastle-Ottawa Scal	ď				
Newcastle-Ottawa Scale	ra Scale								
Study	Representativeness Selection of Determination The result of of the exposed the beginning cohort the beginning the study.	Selection of the unexposed cohort.	Determination of exposure	The result of interest was not at the beginning of the study.	Comparability Assessment of cohorts of outcomes based on design or analysis	y Assessment of outcomes	Follow-up time	Adequacy of Overall score follow-up.	Overall score
Capell et al. Nievera et al. Boyd et al. Borges et al. Hickmann et al. Rebel et al. Lindholz et al. Wolfe et al.	****	* **	****	****	** ***	* ****	****	*****	Moderate quality Moderate quality Moderate quality Moderate quality Moderate quality High quality High quality

tion and the highest level of mobility achieved. Among the strengths of this study is the methodological rigor applied in formulating search strategies, selecting studies, data entry, and data analysis, which contributes to the accuracy and reliability of the findings.

The results of this study have implications for clinical practice, as the included studies encompassed a wide variety of patients with diverse characteristics who underwent early mobilisation and received vasoactive drug infusions at different doses. This study is significant because it suggests that early mobilisation in patients receiving vasoactive drugs could be feasible and appears to be safe, provided that a thorough assessment of the patient's haemodynamic status is conducted to minimise the risk of adverse events associated with the intervention. In this way, the rehabilitation of patients in the ICU is facilitated, and the impacts of ICU-acquired weakness are mitigated. However, given the heterogeneity found in the outcomes measured in the meta-analysis and the quality of some articles, the results should be interpreted with caution.

### **Conclusions**

Early mobilisation in patients with shock and the need for vasoactive drugs is feasible and appears safe in critically ill ICU patients; however, the reference value of vasoactive drug dosage for safe mobilisation in and out of bed is unclear, more studies of high methodological quality are needed to support the reported findings.

# CRediT authorship contribution statement

Henry Mauricio Parada-Gereda, Daniel Molano Franco, Joan Ramon Masclans, and Luis Fernando Pardo contributed substantially to the conception and design, data collection, and data analysis and interpretation. Henry Mauricio Parada-Gereda, Daniel Molano Franco, Joan Ramon Masclans, Janneth Milena Avendaño and Luis Fernando Pardo participated in drafting the manuscript or critically reviewed it for important intellectual content. Henry Mauricio Parada-Gereda, Daniel Molano Franco, Joan Ramon Masclans, Janneth Milena Avendaño and Luis Fernando Pardo gave final approval of the version to be published. Each author participated sufficiently in the work to assume public responsibility for appropriate portions of the content. All authors read and approved the final manuscript.

# Authors' information

The first author of this work is Henry Mauricio Parada-Gereda.

# **Funding**

None.

# **Declaration of competing interest**

The authors declare that they have no competing interests.

# **Acknowledgements**

None.

# Appendix A. Supplementary data

Supplementary material related to this article can be found, in the online version, at doi:https://doi.org/10.1016/j.medine.2024.09.013.

# References

- Herridge MS, Batt J, Hopkins RO. The pathophysiology of long-term neuromuscular and cognitive outcomes following critical illness. Crit Care Clin. 2008;24(1):179–99, http://dx.doi.org/10.1016/j.ccc.2007.11.002. PMID: 18241785.
- Stevens RD, Dowdy DW, Michaels RK, Mendez-Tellez PA, Pronovost PJ, Needham DM. Neuromuscular dysfunction acquired in critical illness: a systematic review. Intensive Care Med. 2007;33(11):1876-91, http://dx.doi.org/10. 1007/s00134-007-0772-2.
- Hermans G, De Jonghe B, Bruyninckx F, Van den Berghe G. Interventions for preventing critical illness polyneuropathy and critical illness myopathy. Cochrane Database Syst Rev. 2014;2014(1):CD006832, http://dx.doi.org/10.1002/14651858.CD006832.pub3.
- Needham DM, Davidson J, Cohen H, Hopkins RO, Weinert C, Wunsch H, et al. Improving long-term outcomes after discharge from intensive care unit: report from a stakeholders' conference. Crit Care Med. 2012;40(2):502-9, http://dx.doi.org/10 .1097/CCM.0b013e318232da75.
- Herridge MS. Legacy of intensive care unit-acquired weakness. Crit Care Med. 2009;37 10 Suppl:S457-61, http://dx.doi.org/10.1097/CCM.0b013e3181b6f35c.
- Pandharipande PP, Girard TD, Ely EW. Long-term cognitive impairment after critical illness. N Engl J Med. 2013; 370(2):185-6, http://dx.doi.org/10.1056/NEJMoa1301372.
- Hashem MD, Parker AM, Needham DM. Early mobilization and rehabilitation of patients who are critically ill. Chest. 2016;150(3):722-31, http://dx.doi.org/10.1016/j.chest.2016.03.003.
- Hodgson CL, Berney S, Harrold M, Saxena M, Bellomo R. Clinical review: early patient mobilization in the ICU. Crit Care. 2013;17(1):207, http://dx.doi.org/10.1186/cc11820.
- Li Z, Peng X, Zhu B, Zhang Y, Xi X. Active mobilization for mechanically ventilated patients: a systematic review. Arch Phys Med Rehabil. 2013;94(3):551-61, http://dx.doi.org/10.1016/j.apmr.2012.10.023.
- Miranda Rocha AR, Martinez BP, Maldaner da Silva VZ, Forgiarini Junior LA. Early mobilization: why, what for and how? Med Intensiva (English Edition). 2017;41(7):429–36, http://dx.doi.org/10.1016/j.medin.2016.10.003.
- 11. Tipping CJ, Harrold M, Holland A, Romero L, Nisbet T, Hodgson CL. The effects of active mobilisation and rehabilitation in ICU on mortality and function: a systematic review. Intensive Care Med. 2017;43(2):171–83, http://dx.doi.org/10.1007/s00134-016-4612-0.
- Bailey P, Thomsen GE, Spuhler VJ, Blair R, Jewkes J, Bezdjian L, et al. Early activity is feasible and safe in respiratory failure patients. Crit Care Med. 2007;35(1):139-45, http://dx.doi.org/10.1097/01.CCM.0000251130.69568.87.
- Stiller K. Physiotherapy in intensive care: an updated systematic review. Chest. 2013;144(3):825-47, http://dx.doi.org/10.1378/chest.12-2930.

- Fuest K, Schaller SJ. Recent evidence on early mobilization in critical-III patients. Curr Opin Anesthesiol. 2018;31(2):144, http://dx.doi.org/10.1097/ACO.00000000000000568.
- Clarissa C, Salisbury L, Rodgers S, Kean S. Early mobilisation in mechanically ventilated patients: a systematic integrative review of definitions and activities. J Intensive Care. 2019;7:3, http://dx.doi.org/10.1186/s40560-018-0355-z.
- 16. S2e guideline: positioning and early mobilisation in prophylaxis or therapy of pulmonary disorders: Revision 2015: S2e guideline of the German Society of Anaesthesiology and Intensive Care Medicine (DGAI) PubMed [Internet]. [Accessed June 25, 2024]. Available at: https://pubmed.ncbi.nlm.nih.gov/26335630/. doi: https://doi.org/10.1007/s00101-015-0071-1.
- 17. Wang TH, Available at: Early Mobilization on Patients with Mechanical Ventilation in the ICU [Internet]. Physical Therapy Effectiveness. IntechOpen; 2020 https://doi.org/10.5772/intechopen.89984
- Dubb R, Nydahl P, Hermes C, Schwabbauer N, Toonstra A, Parker AM, et al. Barriers and strategies for early mobilization of patients in intensive care units. Annals ATS. 2016;13(5):724–30, http://dx.doi.org/10.1513/AnnalsATS.201509-586CME.
- Capell EL, Tipping CJ, Hodgson CL. Barriers to implementing expert safety recommendations for early mobilisation in intensive care unit during mechanical ventilation: a prospective observational study. Aust Crit Care. 2019;32(3):185-90, http://dx.doi.org/10.1016/j.aucc.2018.05.005.
- Alaparthi GK, Gatty A, Samuel SR, Amaravadi SK. Effectiveness, safety, and barriers to early mobilization in the intensive care unit. Crit Care Res Pract. 2020:7840743, http://dx.doi.org/10.1155/2020/7840743.
- 21. Wolfe KS, Patel BK, MacKenzie EL, Giovanni SP, Pohlman AS, Churpek MM, et al. Impact of vasoactive medications on ICU-acquired weakness in mechanically ventilated patients. Chest. 2018;154(4):781–7, http://dx.doi.org/10.1016/j.chest.2018.07.016.
- 22. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1, http://dx.doi.org/10.1186/2046-4053-4-1.
- 23. Ottawa Hospital Research Institute [Internet]. [Accessed October 29, 2023]. Available at: https://www.ohri.ca/programs/clinical\_epidemiology/oxford.asp.
- 24. Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64(4):401–6, http://dx.doi.org/10.1016/j.jclinepi.2010.07.015.
- 25. Boyd J, Paratz J, Tronstad O, Caruana L, Walsh J. Exercise is feasible in patients receiving vasoactive medication in a cardiac surgical intensive care unit: a prospective observational study. Aust Crit Care. 2020;33(3):244-9, http://dx.doi.org/10.1016/j.aucc.2020.02.004.
- 26. Borges LF, Righetti RF, de Souza Francisco D, Yamaguti WP, De Barros CF. Hemodynamic impact of early mobilization in critical patients receiving vasoactive drugs: a prospective cohort study. PLoS One. 2022;17(12 December), http://dx.doi.org/10.1371/journal.pone.0279269.
- 27. Hickmann CE, Castanares-Zapatero D, Bialais E, Dugernier J, Tordeur A, Colmant L, et al. Teamwork enables high level of early mobilization in critically ill patients. Ann Intensive Care. 2016;6(1):80, http://dx.doi.org/10.1186/s13613-016-0184-y.
- 28. Nievera RA, Fick A, Harris HK. Effects of ambulation and nondependent transfers on vital signs in patients receiving norepinephrine. Am J Crit Care. 2016;26(1):31–6, http://dx.doi.org/10.4037/ajcc2017384.
- 29. Rebel A, Marzano V, Green M, Johnston K, Wang J, Neeman T, et al. Mobilisation is feasible in intensive care patients receiving vasoactive therapy: an observational

- study. Aust Crit Care. 2019;32(2):139–46, http://dx.doi.org/10.1016/j.aucc.2018.03.004.
- Lindholz M, Schellenberg CM, Grunow JJ, Kagerbauer S, Milnik A, Zickler D, et al. Mobilisation of critically ill patients receiving norepinephrine: a retrospective cohort study. Crit Care. 2022;26(1):362, http://dx.doi.org/10. 1186/s13054-022-04245-0.
- Annane D, Ouanes-Besbes L, de Backer D, Bin DU, Gordon AC, Hernández G, et al. A global perspective on vasoactive agents in shock. Intensive Care Med. 2018;44(6):833–46, http://dx.doi.org/10.1007/s00134-018-5242-5. Epub 2018 Jun 4. PMID: 29868972.
- 32. Blumlein D, Griffiths I. Shock: aetiology, pathophysiology and management. Br J Nurs. 2022;31(8):422-8, http://dx.doi.org/10.12968/bjon.2022.31.8.422.
- García-Delgado M, Rodríguez-García R, Ochagavía A, Rodríguez-Esteban M de LÁ. The medical treatment of cardiogenic shock.
   Med Intensiva (Engl Ed). 2024;48(8):477–86, http://dx.doi.org/10.1016/j.medine.2024.05.012.
- 34. Levy B, Fritz C, Tahon E, Jacquot A, Auchet T, Kimmoun A. Vasoplegia treatments: the past, the present, and the future. Crit Care. 2018;22:52, http://dx.doi.org/10.1186/s13054-018-1967-3.
- 35. Russell JA. Vasopressor therapy in critically ill patients with shock. Intensive Care Med. 2019;45(11):1503-17, http://dx.doi.org/10.1007/s00134-019-05801-z.
- Leditschke IA, Green M, Irvine J, Bissett B, Mitchell IA. What are the barriers to mobilizing intensive care patients? Cardiopulm Phys Ther J. 2012;23(1):26–9. PMID: 22807652; PMCID: PMC3286497.
- 37. Jolley SE, Regan-Baggs J, Dickson RP, Hough CL. Medical intensive care unit clinician attitudes and perceived barriers towards early mobilization of critically ill patients: a cross-sectional survey study. BMC Anesthesiol. 2014;14:84, http://dx.doi.org/10.1186/1471-2253-14-84.

- 38. Paton M, Chan S, Neto AS, Tipping CJ, Stratton A, Lane R, et al. Association of active mobilisation variables with adverse events and mortality in patients requiring mechanical ventilation in the intensive care unit: a systematic review and meta-analysis. Lancet Respir Med. 2024;12(5):386–98, http://dx.doi.org/10.1016/S2213-2600(24)00011-0.
- 39. TEAM Study Investigators and the ANZICS Clinical Trials GroupHodgson CL, Bailey M, Bellomo R, Brickell K, Broadley T, et al. Early active mobilization during mechanical ventilation in the ICU. N Engl J Med. 2022;387(19):1747–58, http://dx.doi.org/10.1056/NEJMoa2209083.
- Hodgson CL, Stiller K, Needham DM, Tipping CJ, Harrold M, Baldwin CE, et al. Expert consensus and recommendations on safety criteria for active mobilization of mechanically ventilated critically ill adults. Crit Care. 2014;18(6):658, http://dx.doi.org/10.1186/s13054-014-0658-γ.
- 41. Devlin JW, Skrobik Y, Gélinas C, Needham DM, Slooter AJC, Pandharipande PP, et al. Clinical practice guidelines for the prevention and management of pain, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU. Crit Care Med. 2018;46(9):e825, http://dx.doi.org/10.1097/CCM.000000000003299.
- 42. Daum N, Drewniok N, Bald A, Ulm B, Buyukli A, Grunow JJ, et al. Early mobilisation within 72 hours after admission of critically ill patients in the intensive care unit: a systematic review with network meta-analysis. Intensive Crit Care Nurs. 2024;80:103573, http://dx.doi.org/10.1016/j.iccn.2023.103573.
- 43. When is it safe to exercise mechanically ventilated patients in the intensive care unit? An evaluation of consensus recommendations in a cardiothoracic setting. Heart Lung. [Internet]. [Accessed July 12, 2024]. Available at: https://www.heartandlung.org/article/50147-9563(17)30331-X/fulltext. doi: https://doi.org/10.1016/j.hrtlng.2017.11.006.